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Abstract
Background. In pre-hospital situations, delay in resuscitation might carry
extra risks for patients, so resuscitative measures should be rapid, easy-
to use, and effective. A laryngeal mask airway (LMA) is a quickly placed
supraglottic airway that may be used as a route for drug administration.
Vasopressin is a vasopressor and might be absorbed well via the mucosa
of the airways and alveoli. We conducted this animal study to verify the
feasibility of administering vasopressin via a LMA.
Methods. Twenty-four Yorkshire pigs were anesthetized and randomly
divided into four groups. The pigs in Groups Placebo and tracheal tube
(TT) were intubated with a cuffed tracheal tube, and those in Groups
LMA and laryngeal mask airway and a catheter (LMAC) underwent a size
4 LMA insertion. In the LMAC group, an aerosolized catheter was placed
into the trachea through a LMA to deliver the drug. All pigs were able to
breathe spontaneously without the assistance of a ventilator. The placebo
group received 5 ml of distilled water via a tracheal tube. The other
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groups received 1 U/kg vasopressin, which was diluted to a total volume
of 5 ml with distilled water via the varied routes. The heart rates and
arterial pressures were recorded before and after drug administration.
Results. The mean arterial pressure (MAP) and diastolic arterial pressure
(DAP) increased significantly and maintained a plateau from 3 to 7 min
in Group TT and 2 to 29 min in Group LMAC. Group LMA and Group
Placebo demonstrated only one occasional elevation in MAP and no
changes in DAP. Furthermore, the heart rate decreased significantly from
2 to 29 min in Group LMAC.
Conclusions. In this porcine model, vasopressin administered via an
aerosolized catheter and ventilated with a LMA demonstrated a positive
and prolonged pressor effect. The results suggest that an aerosolized
catheter placed through a LMA, may be a practical alternative route for
vasopressin administration, and that the effective duration of
vasopressin is long enough to cover the period of pre-hospital
management.
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Introduction
In pre-hospital situations, the feasibility of varied resuscitative
management is crucial for patients and emergency medical technicians
(EMTs). Out-of-hospital management should be rapid, easy-to use, and
effective, even in rigorous situations. A prolonged stay at the scene might
carry extra risks for patients. (1,2)
Intravenous, intraosseous, and administration via tracheal tube, are all
practical methods for pre-hospital drug delivery. However, establishment
of these routes is usually difficult and time-consuming in out-of-hospital
situations. (3-5) These procedures prolong the length of stay and might
be misplaced at the scene. (3,5)
A laryngeal mask airway (LMA) is an effective supraglottic airway device
and is widely used by EMTs. A LMA can be placed quickly and easily by
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unfamiliar healthcare workers and the skill can be retained without
frequent training. (6,7) Furthermore, previous studies have revealed its
potential to serve as a route for drug administration. (8-10)
Vasopressin is a potent vasopressor with extended purposes in the
treatment of severe trauma, septic shock, cardiac diseases and during
cardiopulmonary resuscitation. (11-22) In addition, a few researchers
have found that vasopressin is absorbed well via the mucosa of the
airway and alveoli. (23-25) The combination of a LMA and vasopressin
could be a practical management tool in pre-hospital settings.
Accordingly, we conducted this animal study to verify the feasibility of
administering vasopressin via a LMA.
Materials and methods
The project was approved by the animal investigation committee of Chi-
Mei Medical Center. The animals were managed in accordance with
national and institutional guidelines. Sixteen female and 8 male
Yorkshire pigs, with an average weight of 22.1 kg (range 16.5-25.7 kg;
median 22.5 kg), were used in this study (table 1). Before the experiment,
the pigs were fasted overnight but given unrestricted access to water. The
animals were premedicated with Tiletamine/Zolazepam (2.5 mg/kg)
intramuscularly and were fixed in a dorsal recumbent position.
Anesthesia was inducted with 10 mg/kg pentothal injected into an ear
vein. All of the pigs were able to breathe spontaneously without
ventilator assistance and none of the animals needed an additional
anesthetic agent to maintain anesthesia during the experiment. A
femoral artery was catheterized for continuous arterial pressure and
heart rate monitoring, and 3000U intravenous heparin was administered
to avoid intra-catheter clot formation. The pigs were then randomly
divided into four groups, with each group comprising 6 animals. The
animals in the Placebo and tracheal tube (TT) groups were intubated
with a cuffed tracheal tube (internal diameter 7 mm) and those in the
LMA and laryngeal mask airway and a catheter (LMAC) groups
underwent a size 4 LMA (LMA-ClassicTM; The Laryngeal Mask
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Company, Henley on Thames, UK) insertion. In the LMAC group, a
catheter (MADett®; Wolfe Tory Medical, Salt Lake City, America) was
placed into the trachea through the LMA to deliver the medication. The
catheter was designed to aerosolize the injected solution, which
facilitated the absorption of the drug. We used a fibrobronchoscopy to
confirm the position of the tracheal tube, ensure that the opening of the
larynx was faced directly towards the lower aperture of the LMA, and
verify that the tip of the MADett® catheter was located in the trachea.
After completing the above procedures, we allowed a 20-minute
stabilization period to achieve a steady state.
Group Placebo: 5 ml of distilled water was administered via the tracheal
tube.
Group TT: 1 U/Kg of vasopressin, diluted to a total volume of 5 ml with
distilled water, was administered via the tracheal tube.
Group LMA: 1 U/Kg of vasopressin, diluted to a total volume of 5 ml with
distilled water, was administered via the upper end of the LMA.
Group LMAC: 1 U/Kg of vasopressin, diluted to a total volume of 5 ml
with distilled water, was administered via the MADett® catheter.
Five forceful artificial ventilations were given via tracheal tube or LMA to
help the spraying of medication after various drugs were administered.
The heart rate and arterial pressure were recorded before administration,
at 30 seconds after drug administration, every minute for 9 minutes, and
then every 2 minutes for 29 minutes. At the end of the experiment, the
animals were killed using an injection of potassium chloride solution 10
mEq.
The results are presented as medians, unless otherwise stated.
Differences in heart rate and arterial pressure between the four groups
were compared using the Kruskal-Wallis test, followed by the Mann-
Whitney U test. Using the data before drug administration as the
baseline, changes in hemodynamic variables were investigated using the
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Friedman test followed by the Wilcoxon signed rank test. All statistical
tests were performed using SPSS software package (SPSS 12.0), with a
two-tailed significance level of 0.05.
Results
After drugs were administered via varied routes, the mean arterial
pressure (MAP) and diastolic arterial pressure (DAP) of Group LMAC
decreased significantly at 0.5 minutes and returned to baseline soon
after, at 1 minute postinjection. Both MAP and DAP then increased
significantly and maintained a plateau from 2 to 29 minutes. Similarly,
Group TT showed a drop in MAP and DAP at 0.5 minutes and resumed
baseline levels after vasopressin administration. Thereafter, the MAP
and DAP elevated significantly from 3 to 7 minutes and the peak levels
were higher than those of other groups. The DAP demonstrated no
changes and the MAP demonstrated one occasional rise at 4 minutes in
Group Placebo and at 7 minutes in Group LMA (figure 1,2).
The heart rates in Group Placebo were higher than in other groups, but
there were no statistically significant differences between Group Control
and TT, or Group Placebo and LMA. Groups Placebo, TT and LMA
showed no persistent changes in heart rate after vasopressin
administration. In Group LMAC, the heart rate decreased significantly at
2 minutes after drug delivery and maintained a lower level until 29
minutes (figure 3).
Discussion
Vasopressin administered via tracheal tube elevated the MAP and DAP in
the experimental animals, a finding that is in line with previous research.
(23-25) Nevertheless, vasopressin delivered from the LMA did not
demonstrate any apparent hemodynamic changes, which limits the
application of vasopressin administration directly from a LMA. The
insignificant hemodynamic changes may be due to several factors. First,
vasopressin injected from the upper end of a LMA sprays most of the
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drug on the mucosa of the larynx instead of the much larger surface of
the bronchoalveolar system. The smaller surface limits the absorption of
vasopressin and results in unobvious pharmacologic effects. Moreover,
during forceful artificial ventilations after drug delivery, ventilating air
and drugs might leak from the lower aperture of the LMA, which further
impedes the distribution of vasopressin. (6,26)
The vasopressin in Group LMAC presented rapid, constant, and
prolonged hemodynamic changes. The catheter aerosolized the injected
solution into fine particles, which distributed the drugs to the
bronchoalveolar system well and improved drug absorption. We
conducted a manikin study for the feasibility of catheter placement
through a LMA and found that placement of the catheter was fast, easy,
and required minimal training. (27) Accordingly, vasopressin should be
administered via a catheter passing through a LMA.
For the management of hemorrhagic shock, early large-volume fluid
infusions have not proven to be effective due to the number of
complications, including coagulopathy, multiorgan failure, promotion of
additional blood loss, and hypothermia. (28,29) Nevertheless, the delay
in fluid resuscitation causes a shortage of requisite end-organ perfusion
that can result in early mortality in severe trauma patients. (11,12)
Animal studies demonstrate that vasopressin increases blood pressure
and prevents hypovolemic cardiac arrest from fatal hemorrhage. (11,12)
In addition, to improve perfusion pressure of vital organs, exogenous
administration of vasopressin provides the added benefit of enhancing
clot formation. (13) Therefore, it seems reasonable to consider
vasopressin for treating hemorrhagic shock patients at the scene.
In patients with septic shock, the development of relative vasopressin
deficiency provides the rationale for using vasopressin as an adjunct to
catecholamine. (14,15) Neto et al. conducted a systemic review and meta-
analysis on the use of vasopressin and its analogue in critically ill
patients. It was found that vasopressin decreased mortality in adult
patients and in patients with septic shock. (16) Observational studies
have shown some benefits involving early, low-dose vasopressin
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administration in patients with septic shock. (14,17) Our experiment
demonstrated that vasopressin administered via an aerosolized catheter
through a LMA produces an obvious and constant pressor effect, which
implies the possibility of a favorable influence on pre-hospital
application of vasopressin.
The cardiopulmonary resuscitation guidelines for the American Heart
Association have recommended intravenous vasopressin for the
treatment of adult patients with cardiac arrest. (18) Various human and
animal studies have also shown beneficial effects from the addition of
vasopressin during resuscitation, including increased coronary perfusion
pressure, cerebral oxygen delivery, the probability of restoring
spontaneous circulation, and better neurologic outcome. (19-21) For
cardiogenic shock patients, Jolly et al. found that vasopressin increased
mean arterial pressure and displayed no adverse cardiac effect. (22) This
evidence further supports the use of vasopressin in cardiopulmonary
resuscitation, treatment of patients with cardiogenic shock, and cerebral
hemorrhage. Furthermore, in our experiment, we found that only one
dose of vasopressin, elevated arterial pressures for at least 27 minutes in
Group LMAC. The effectiveness of a single dose of vasopressin could be
sufficient for pre-hospital resuscitation and transportation in an urban
area. (30,31)
We found that vasopressin significantly reduces heart rate, and the
bradycardiac effect could prevent the progression of tachycardia induced
by cardiomyopathy. (32) Diastolic dysfunction is a major predictor of
mortality in patients with septic shock and reduction of the heart rate in
patients with diastolic dysfunction can achieve better ventricular filling.
(33) If preexisting bradycardia is found before vasopressin
administration, pre-treatment with tracheal atropine can antagonize the
effect. (34)
There were several limitations that influenced the application of the
study results. First, the LMA is designed for humans and fits loosely in a
pig larynx. Obvious air leaks were expected when artificial ventilations
were conducted via LMA in the experimental pigs, which may
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compromise the absorption of vasopressin. In addition, as all of the pigs
were healthy prior to the experiment, the pharmacodynamics in a
healthy porcine model may differ from animals in cardiac arrest or shock
states.
Conclusion
In this porcine model, vasopressin, administered via an aerosolized
catheter and ventilated with a LMA, demonstrated a positive and
prolonged pressor effect. The results suggest that an aerosolized catheter
through a LMA may be a practical alternative route for vasopressin
administration, to provide a rapid and constant drug effect.
Furthermore, the effective duration of LMA-administered vasopressin is
long enough to cover the interval for pre-hospital resuscitation and
transportation. Because placement of a LMA and catheter are fast and
easy, we suggest conducting further studies for the utilization of
vasopressin, aerosolized catheters, and LMAs in pre-hospital settings.
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Table 1. Biometric data.
Group Placebo TT LMA LMAC
M/F 2/4 2/4 1/5 3/3










F, female; LMA, laryngeal mask airway; LMAC, laryngeal mask airway
and a catheter; M, male; TT, tracheal tube.
Figure 1.
In Group TT and Group LMAC, the MAP decreased significantly at 0.5
minutes and returned to baseline soon after, at 1 minute after drug
administration. The MAP then increased significantly and maintained a
plateau from 3 to 7 minutes in Group TT and from 2 to 29 minutes in
Group LMAC. The peak level of MAP in Group TT was higher than in
other groups. Furthermore, the MAP demonstrated one occasional rise at
4 minutes in Group Placebo and at 7 minutes in Group LMA.
LMA, laryngeal mask airway; LMAC, laryngeal mask airway and a
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catheter; MAP, mean arterial pressure; TT, tracheal tube.
**◆: The MAP is significantly higher than the baseline, p < 0.05 
***●: The MAP is significantly lower than the baseline, p < 0.05
 
Figure 2.
In Group TT and Group LMAC, the DAP decreased significantly at 0.5
minutes and returned to baseline soon after, at 1 minute after drug
administration. The DAP then increased significantly and maintained a
plateau from 3 to 7 minutes in Group TT and from 2 to 29 minutes in
Group LMAC. The peak level of DAP in Group TT was higher than in
other groups. In Group Placebo and Group LMA, the DAP demonstrated
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no significant differences from the baseline.
DAP, diastolic arterial pressure; LMA, laryngeal mask airway; LMAC,
laryngeal mask airway and a catheter; TT, tracheal tube.
**◆: The DAP is significantly higher than the baseline, p < 0.05 
***●: The DAP is significantly lower than the baseline, p < 0.05
 
Figure 3.
The heart rate after drug administration was highest in Group Placebo
and lowest in Group LMAC. In Groups Placebo, TT and LMA, the heart
rate showed no constant changes after drug delivery. In Group LMAC,
the heart rate decreased significantly at 2 minutes after vasopressin
administration and the bradycardiac effect was prolonged.
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HR, heart rate; LMA, laryngeal mask airway; LMAC, laryngeal mask
airway and a catheter; TT, tracheal tube.
**●: The HR is significantly lower than the baseline, p < 0.05
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